论文部分内容阅读
目的探讨不同量盐酸坦索罗辛治疗良性前列腺增生(BPH)患者引起的下尿路症状(LUTS)的治疗效果及对不同体重患者的影响。方法选择BPH伴LUTS患者236例,随机分为剂量A组和剂量B组,分别给予0.2mg每晚1次和0.4mg每晚1次口服盐酸坦索罗辛,比较两组IPSS、IIEF-5、QOL、Qmax、Qave及PVR。结果剂量A、B组治疗后1、3个月IPSS、IIEF-5、QOL、Qmax、Qave及PVR较治疗前显著改善(P<0.05),组间差异均无统计学意义(P>0.05)。两组不良反应率差异无统计学意义(P>0.05)。体重≤70kg的患者采用剂量A、B治疗后1、3个月IPSS、Qmax、Qave及PVR变化值之间差异无统计学意义(P>0.05),体重>70kg的患者采用剂量B治疗后1、3个月IPSS、Qmax、Qave及PVR变化值显著高于采用剂量A的患者(P<0.05)。结论 0.4mg剂量与常规剂量的盐酸坦索罗辛治疗BPH伴LUTS总体效果和安全性相似,对于>70kg的较大体重患者获益更稳定。较大体重患者在常规剂量效果不佳时建议采用大剂量盐酸坦索罗辛治疗。
Objective To investigate the therapeutic effect of different doses of tamsulosin on lower urinary tract symptoms (LUTS) in patients with benign prostatic hyperplasia (BPH) and its effects on patients with different body weight. Methods Totally 236 BPH patients with LUTS were randomly divided into dose A group and dose B group, given 0.2mg once night and 0.4mg once daily. Tamsulosin hydrochloride was given orally. Compared with the two groups, IPSS, IIEF-5 , QOL, Qmax, Qave and PVR. Results The IPSS, IIEF-5, QOL, Qmax, Qave and PVR in group A and group B after treatment were significantly improved (P <0.05), but there was no significant difference between groups (P> 0.05) . There was no significant difference in adverse reaction rate between the two groups (P> 0.05). There was no significant difference in the changes of IPSS, Qmax, Qave and PVR between the patients with body weight of 70kg and the doses of A and B at 1 and 3 months (P> 0.05) , And the changes of IPSS, Qmax, Qave and PVR at 3 months were significantly higher than those at dose A (P <0.05). CONCLUSION: The 0.4 mg dose is similar to the conventional dose of tamsulosin in the treatment of BPH with LUTS overall, with similar safety and benefit for patients with larger body weights greater than 70 kg. Larger weight patients in the conventional dose ineffective recommended high dose tamsulosin hydrochloride treatment.